본문 바로가기
KERD
논문KCI 등재

Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison

Bo Hyun Kim|Joong-Won Park|Yuri Cho
대한간학회 (The korean Association for the Study of the Liver)|2023.04|Clinical and Molecular Hepatology|제29권 제2호|pp. 252-262

2

조회

0

다운로드

9

인용

0

참고문헌

키워드

AsiaPractice guidelineHepatocellular carcinomaChronic hepatitis B

초록

Hepatocellular carcinoma (HCC) is highly prevalent and the third most common cause of cancer-related death in Asia. In contrast to the West, the main etiology of HCC in many Asian countries except Japan is chronic hepatitis B virus infection. Differences in the major causes of HCC lead to significant clinical and treatment differences. This review summarizes and compares guidelines on managing HCC from China, Hong Kong, Taiwan, Japan, and South Korea. From oncology and socio-economic perspectives, factors such as underlying diseases, staging methods, government policies, insurance coverage, and medical resources contribute to varying treatment strategies among countries. Furthermore, the differences in each guideline are fundamentally caused by the lack of incontrovertible medical evidence, and even existing results of clinical trials can be interpreted differently. This review will provide a complete overview of the current Asian guidelines for HCC in recommendations and in practice.

Abstract

Hepatocellular carcinoma (HCC) is highly prevalent and the third most common cause of cancer-related death in Asia. In contrast to the West, the main etiology of HCC in many Asian countries except Japan is chronic hepatitis B virus infection. Differences in the major causes of HCC lead to significant clinical and treatment differences. This review summarizes and compares guidelines on managing HCC from China, Hong Kong, Taiwan, Japan, and South Korea. From oncology and socio-economic perspectives, factors such as underlying diseases, staging methods, government policies, insurance coverage, and medical resources contribute to varying treatment strategies among countries. Furthermore, the differences in each guideline are fundamentally caused by the lack of incontrovertible medical evidence, and even existing results of clinical trials can be interpreted differently. This review will provide a complete overview of the current Asian guidelines for HCC in recommendations and in practice.

참고문헌 (39)

  1. Ran Xu Zhu, "Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region", Gut and Liver, 10(3), pp.332~339 (2016), 거트앤리버 소화기연관학회협의회
  2. 김보현, "Epidemiology of liver cancer in South Korea", Clinical and Molecular Hepatology, 24(1), pp.1~9 (2018), 대한간학회
  3. Young Eun Chon, "Hepatocellular carcinoma statistics in South Korea", Clinical and Molecular Hepatology, 27(3), pp.512~514 (2021), 대한간학회[DOI]
  4. Llovet JM, "Prognosis of hepatocellular carcinoma : the BCLC staging classification", Semin Liver Dis, 19, pp.329~338 (1999)
  5. Bruix J, "Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver", J Hepatol, 35, pp.421~430 (2001)
  6. Park JW, "Practice guideline for diagnosis and treatment of hepatocellular carcinoma", Korean J Hepatol, 10, pp.88~98 (2004)
  7. Makuuchi M, "Clinical practice guidelines for hepatocellular carcinoma : the first evidence based guidelines from Japan", World J Gastroenterol, 12, pp.828~829 (2006)
  8. Kudo M, "Management of hepatocellular carcinoma in Japan : consensus-based clinical practice manual proposed by the Japan Society of Hepatology", Oncology, 72(Suppl 1), pp.2~15 (2007)
  9. Yau T, "Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma", Gastroenterology, 146, pp.1691~1700 (2014)
  10. Zhou J, "Guidelines for the diagnosis and treatment of hepatocellular carcinoma(2019 edition)", Liver Cancer, 9, pp.682~720 (2020)
  11. Shao YY, "Management consensus guideline for hepatocellular carcinoma : 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan", J Formos Med Assoc, 120, pp.1051~1060 (2021)
  12. Kudo M, "Management of hepatocellular carcinoma in Japan : JSH Consensus Statements and Recommendations 2021Update", Liver Cancer, 10, pp.181~223 (2021)
  13. Omata M, "AsiaPacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
  14. Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(4), pp.583~705 (2022), 대한간학회
  15. Cheung TT, "The Hong Kong consensus statements on unresectable hepatocellular carcinoma : narrative review and update for 2021", Hepatobiliary Surg Nutr (2022)[DOI]
  16. Kim Y, "Overview of the National Cancer screening programme and the cancer screening status in Korea", Asian Pac J Cancer Prev, 12, pp.725~730 (2011)
  17. Surveillance group, "Management consensus guideline for hepatocellular carcinoma : 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan", J Formos Med Assoc, 117, pp.381~403 (2018)
  18. Zhou J, "Guidelines for diagnosis and treatment of primary liver cancer in china(2017 edition)", Liver Cancer, 7, pp.235~260 (2018)
  19. Gupta P, "Abbreviated MRI for hepatocellular carcinoma screening : A systematic review and meta-analysis", J Hepatol, 75, pp.108~119 (2021)
  20. 이상민, "Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018", Korean Journal of Radiology, 22(7), pp.1066~1076 (2021), 대한영상의학회[DOI]
  21. 이선영, "Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging", Clinical and Molecular Hepatology, 26(3), pp.340~351 (2020), 대한간학회[DOI]
  22. Terzi E, "Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules", J Hepatol, 68, pp.485~492 (2018)
  23. Xie DY, "2019 Chinese clinical guidelines for the management of hepatocellular carcinoma : updates and insights", Hepatobiliary Surg Nutr, 9, pp.452~463 (2020)
  24. Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : The 2022 update", J Hepatol, 76, pp.681~693 (2022)
  25. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
  26. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 Practice Guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
  27. Rex Wan-Hin Hui, "Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Hong Kong perspective", Clinical and Molecular Hepatology, 29(2), pp.217~229 (2023), 대한간학회
  28. Diyang Xie, "Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective", Clinical and Molecular Hepatology, 29(2), pp.206~216 (2023), 대한간학회
  29. Sun J, "Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China(2021 edition)", Liver Cancer, 11, pp.315~328 (2022)
  30. Tung-Hung Su, "Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective", Clinical and Molecular Hepatology, 29(2), pp.230~241 (2023), 대한간학회
  31. Hasegawa K, "Clinical Practice Guidelines for Hepatocellular Carcinoma : The Japan Society of Hepatology 2021 version(5th JSH-HCC Guidelines)", Hepatol Res (2023)[DOI]
  32. Lee IJ, "Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients", Ther Adv Med Oncol, 11, pp.1758835919866072~ (2019)
  33. Joseph C Ahn, "Systemic therapy in advanced hepatocellular carcinoma", Clinical and Molecular Hepatology, 29(2), pp.516~519 (2023), 대한간학회
  34. Kim TH, "Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma : A randomized phase III trial", J Hepatol, 74, pp.603~612 (2021)
  35. Myung Ji Goh, "Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective", Clinical and Molecular Hepatology, 29(2), pp.197~205 (2023), 대한간학회
  36. Racanelli V, "The liver as an immunological organ", Hepatology, 43(2 Suppl 1), pp.S54~S62 (2006)
  37. Doherty DG, "Antigen-specific immune tolerance in the liver", Nat Biomed Eng, 3, pp.763~765 (2019)
  38. Finn RS, "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
  39. Abou-Alfa GK, "Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma", NEJM Evid, 1, pp.EVIDoa2100070~ (2022)

관련 논문AI추천

2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular CarcinomaKorean Liver Cancer Association (KLCA) and National Cancer Center (NCC거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제3호Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Hong Kong perspectiveLung-Yi Mak, Man-Fung Yuen, Rex Wan-Hin Hui, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinomaKorean Liver Cancer Association (KLCA), National Cancer Center (NCC) Korea대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제4호Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspectiveDong Ho Hyun, Dong Hyun Sinn, Jeong Il Yu, Jong Man Kim, Jung Yong Hong, Min Woo Lee, Moon Seok Choi, Myung Ji Goh대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspectiveDiyang Xie, Jia Fan, Jian Zhou, Jieyi Shi, Qiang Gao대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma한국 간 암 스터디그룹, 국립 암 센터거트앤리버 소화기연관학회협의회 · Gut and Liver2015 · 제9권 제3호

이 간행물의 다른 논문 (53건)

Congratulatory remarksSi Hyun Baepp. 1-1Special thanksSeung Up Kimpp. 4-4MAFLD: How is it different from NAFLD?Ming-Hua Zheng, Jacob George, Cameron Gofton, Yadhavan Upendranpp. 17-31Global incidence and prevalence of nonalcoholic fatty liver diseaseEunice Tan, Mark D. Muthiah, Cheng Han Ng, Margaret LP Teng, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Daniel Q. Huangpp. 32-42Nonalcoholic fatty liver disease and non-liver comorbiditiesRichie Manikat, Mindie H. Nguyenpp. 86-102
원문 보기